Two new studies show that mechanisms of acquired resistance to targeted therapy in lung cancer do not necessarily pre-exist in resistant subclones. Instead, some cancers may harbor the potential to acquire a variety of drug-resistance mechanisms after response to targeted therapy.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The Contribution of Evolutionary Game Theory to Understanding and Treating Cancer
Dynamic Games and Applications Open Access 30 August 2021
-
The emerging role of ferroptosis in intestinal disease
Cell Death & Disease Open Access 17 March 2021
-
New insights from the widening homogeneity perspective to target intratumor heterogeneity
Cancer Communications Open Access 04 May 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hata, A.N. et al. Nat. Med. 22, 262–269 (2016).
Ramirez, M. et al. Nat. Commun. 7, 10.1038/ncomms10690 (19 February 2016).
Arcila, M.E. et al. Clin. Cancer Res. 17, 1169–1180 (2011).
Zhou, W. et al. Nature 462, 1070–1074 (2009).
Chmielecki, J. et al. Sci. Transl. Med. 3, 90ra59 (2011).
Jänne, P.A. et al. N. Engl. J. Med. 372, 1689–1699 (2015).
Ye, X., et al. J. Thorac. Oncol. 8, 1118–1120 (2013).
Sharma, S.V. et al. Cell 141, 69–80 (2010).
Engelman, J.A. et al. Science 316, 1039–1043 (2007).
Tricker, E.M. et al. Cancer Discov. 5, 960–971 (2015).
Oxnard, G.R. et al. Clin. Cancer Res. 20, 1698–1705 (2014).
Thress, K.S. et al. Nat. Med. 21, 560–562 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
G.R.O. has received consulting fees from Ariad, AstraZeneca, Boehringer-Ingehleim, Clovis and Genentech.
Rights and permissions
About this article
Cite this article
Oxnard, G. The cellular origins of drug resistance in cancer. Nat Med 22, 232–234 (2016). https://doi.org/10.1038/nm.4058
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4058
This article is cited by
-
The Contribution of Evolutionary Game Theory to Understanding and Treating Cancer
Dynamic Games and Applications (2022)
-
Targeted therapy for drug-tolerant persister cells after imatinib treatment for gastrointestinal stromal tumours
British Journal of Cancer (2021)
-
The emerging role of ferroptosis in intestinal disease
Cell Death & Disease (2021)
-
Overcoming therapy resistance in EGFR-mutant lung cancer
Nature Cancer (2021)
-
Bacterial persistence promotes the evolution of antibiotic resistance by increasing survival and mutation rates
The ISME Journal (2019)